Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

CONTEXT: There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a medical therapy would be a valuable therapeutic option for the management of this disorder. OBJECTIVE: Our objective was to evaluate the short-term efficacy of the nov...

Full description

Bibliographic Details
Main Authors: Boscaro, M, Ludlam, W, Atkinson, B, Glusman, J, Petersenn, S, Reincke, M, Snyder, P, Tabarin, A, Biller, B, Findling, J, Melmed, S, Darby, C, Hu, K, Wang, Y, Freda, P, Grossman, AB, Frohman, L, Bertherat, J
Format: Journal article
Language:English
Published: 2009

Similar Items

Similar Items